Larimar Therapeutics Highlights Promising Friedreich’s Ataxia Data
I'm PortAI, I can summarize articles.
Larimar Therapeutics (LRMR) announced promising data for nomlabofusp as a treatment for Friedreich’s Ataxia, showing significant improvements in frataxin levels and clinical outcomes. The company plans to submit a Biologics License Application by Q2 2026 for accelerated approval. Despite some adverse reactions, the therapy was generally well tolerated. Analysts rate LRMR stock as a Buy with a $21.00 price target, though concerns about high R&D costs and lack of profitability lead to a Neutral score from TipRanks’ AI Analyst. Larimar focuses on therapies for rare diseases, with a current market cap of $296.1M.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments